156 related articles for article (PubMed ID: 16408158)
1. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
Iannello A; Ahmad A
Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
[TBL] [Abstract][Full Text] [Related]
2. Combination strategies to enhance antitumor ADCC.
Kohrt HE; Houot R; Marabelle A; Cho HJ; Osman K; Goldstein M; Levy R; Brody J
Immunotherapy; 2012 May; 4(5):511-27. PubMed ID: 22642334
[TBL] [Abstract][Full Text] [Related]
3. Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics.
Dalziel M; Beers SA; Cragg MS; Crispin M
Glycobiology; 2018 Sep; 28(9):697-712. PubMed ID: 29800150
[TBL] [Abstract][Full Text] [Related]
4. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
Alderson KL; Sondel PM
J Biomed Biotechnol; 2011; 2011():379123. PubMed ID: 21660134
[TBL] [Abstract][Full Text] [Related]
5. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.
Wang QS; Wang Y; Lv HY; Han QW; Fan H; Guo B; Wang LL; Han WD
Mol Ther; 2015 Jan; 23(1):184-91. PubMed ID: 25174587
[TBL] [Abstract][Full Text] [Related]
6. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.
Cronin KA; Lake AJ; Scott S; Sherman RL; Noone AM; Howlader N; Henley SJ; Anderson RN; Firth AU; Ma J; Kohler BA; Jemal A
Cancer; 2018 Jul; 124(13):2785-2800. PubMed ID: 29786848
[TBL] [Abstract][Full Text] [Related]
7. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
[TBL] [Abstract][Full Text] [Related]
9. Overview of systemic therapy for colorectal cancer.
Goodwin RA; Asmis TR
Clin Colon Rectal Surg; 2009 Nov; 22(4):251-6. PubMed ID: 21037816
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Curran MA; Montalvo W; Yagita H; Allison JP
Proc Natl Acad Sci U S A; 2010 Mar; 107(9):4275-80. PubMed ID: 20160101
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Nomi T; Sho M; Akahori T; Hamada K; Kubo A; Kanehiro H; Nakamura S; Enomoto K; Yagita H; Azuma M; Nakajima Y
Clin Cancer Res; 2007 Apr; 13(7):2151-7. PubMed ID: 17404099
[TBL] [Abstract][Full Text] [Related]
12. Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering.
Lee D; Dunn ZS; Guo W; Rosenthal CJ; Penn NE; Yu Y; Zhou K; Li Z; Ma F; Li M; Song TC; Cen X; Li YR; Zhou JJ; Pellegrini M; Wang P; Yang L
Nat Commun; 2023 Nov; 14(1):6942. PubMed ID: 37938576
[TBL] [Abstract][Full Text] [Related]
13. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.
Taha Z; Crupi MJF; Alluqmani N; Fareez F; Ng K; Sobh J; Lee E; Chen A; Thomson M; Spinelli MM; Ilkow CS; Bell JC; Arulanandam R; Diallo JS
Front Immunol; 2023; 14():1181014. PubMed ID: 37153626
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
Zhang Z; Xu Q; Huang L
Front Immunol; 2023; 14():1126421. PubMed ID: 36855629
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens.
Helmy YA; Taha-Abdelaziz K; Hawwas HAE; Ghosh S; AlKafaas SS; Moawad MMM; Saied EM; Kassem II; Mawad AMM
Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830185
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
17. Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.
Mokhtary P; Pourhashem Z; Mehrizi AA; Sala C; Rappuoli R
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009408
[TBL] [Abstract][Full Text] [Related]
18. Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
Rotte A; Sahasranaman S; Budha N
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572463
[TBL] [Abstract][Full Text] [Related]
19. Role of Toll-like receptors in natural killer cell function in acute lymphoblastic leukemia.
Gallardo-Zapata J; Maldonado-Bernal C
Oncol Lett; 2021 Nov; 22(5):748. PubMed ID: 34539852
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin signaling in cancers and targeted therapies.
Yu F; Yu C; Li F; Zuo Y; Wang Y; Yao L; Wu C; Wang C; Ye L
Signal Transduct Target Ther; 2021 Aug; 6(1):307. PubMed ID: 34456337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
